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Purpose: The purpose of this research project was to pilot and validate a new instrument to 
measure firm intellectual property (IP) management practices. 
 
Methodology/Approach: A survey instrument was developed in consultation with a Perth-
based firm of patent attorneys specialising in IP management services. The survey was 
piloted by random mail-out to 357 biotechnology firms, 68 of which returned a useable 
response. IP managers’ responses to the following seven dimensions of extent of IP 
management practice were measured on a 5-point Likert-scale: 1) Record-keeping and 
management practices (22 items); 2) IP capture and protection mechanisms (10 items); 3) 
Use of IP management services or traditional patent attorney services (9 items); 4) Defensive 
measures (12 items); 5) Business Plan and strategic vision (9 items); 6) Knowledge of the IP 
landscape (9 items); and, 7) Promoting an IP culture (7 items). Factor Analysis and Principle 
Component Analysis extraction method with Varimax Rotation were used to identify factors 
measured by our instrument.  
 
Findings: Between two and seven factors were extracted for each of the dimensions 
measuring IP management practices, explaining between 51% (IP Defensive Measures) to 
74% (IP management services and traditional patent attorney services) of the cumulative 
variance on any one factors. Scrutiny of the Component Matrices for a common thread 
amongst large loadings indicated thirteen actual measures of IP management practices 
perceived by biotechnology firm IP managers; with high Cronbach’s Alpha reliability.  
 
Research limitations/implications: Factor analysis of this instrument revealed that IP 
managers’ responses were loading on 13 factors instead of the original 7 anticipated 
dimensions to the measure. The spread of 78 item was reduced to a more relevant and 
economical measure with 56 items. As scrutiny of the factor analysis has revealed increasing 
heterogeneity to IP management practices in the biotechnology industry, it might be 
interesting to repeat the study for IP managers in another industry. A limitation of the study 
is its Australian biotechnology context and also that no concession was made in the measure 
for the effect of firm vertical disintegration. 
 
Originality/value: To our knowledge this is a novel project. We have validated and 
streamlined a new IP management practices instrument with advice from a practicing firm of 
IP management consultants. The instrument should be useful to high-technology firms as a 
checklist of IP management practices for innovation management. It should also be a 
valuable measurement tool for academics, firms and industries wanting to characterise the 




Published research about Intellectual property (IP) can be categorized by subject matter as 
follows: 1) studies that examine the legal nature of patents and international patent law; 2) 
enforcement and disputes related studies, often focussed on the ramifications of infringement; 
3) consideration of the microeconomic effects of IP protection, monopoly and effect of 
protectionist policy and regulatory framework; 4) studies that examine IP protection from 
different industry perspectives focussing on unique attributes of high-technology, research 
and development (R&D) focussed firms; 5) investigations of firm-related determinants of IP 
strategy such as size, training and IP personnel; 6) empirical studies that attempt to quantify 
the value of IP; and, 7) intellectual property management studies (summary from an excellent 
recent review by Hansel (2006)). The subject of the current research project is closest in 
subject matter to 4) and 7) above - an industry-specific investigation of IP management 
practices.  
 
Intellectual capital is notoriously difficult to define (Roos et al., 2005; p. 19). Intellectual 
property (IP) as a subset of intangible firm value is often registered, with associated legal 
costs capitalized in financial reports, and considerable disclosure in the firm’s annual report 
(patents and trademarks), and on the firm website. Less tangible IP is more often hidden from 
investors (trade secrets, copyright and design are less obvious examples of property that is 
IP). Traditionally registered IP rights are part of the ‘Organisational Capital’ classification of 
intellectual capital (Stewart, 1997). 
 
In an interesting study of the networking and integration of IP into business process by 
Mouritsen and Koleva (2005) investigated the business environment setup around patented IP 
rights. Through case study analysis of Palm Computing Inc. and Polaroid, the authors discuss 
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patents as networked objects - as a driving-force responsible for integrated management. The 
authors theorise that:  
 
“…the concreteness of managing patents play out many more dimensions, and 
that to make patents valuable requires a somewhat more complex management 
agenda”, and, “… the patent, when it works, develops surprising relations that can 
hardly be captured in a finite resource allocation mechanism” (p. 316) 
 
The aim of this paper was to validate an instrument which, in future studies, can be used to 
empirically capture some of the relational determinants of IP property rights identified by 
Mouritsen and Koleva above. In considering IP management practices of active IP managers 
in the life sciences sector, our paper attempts to disaggregate the processes that accountants 
and IP management consultants perceive as important for establishment of sound and 
defendable IP rights; there are many important network players. The measures’ individual 
items which loaded during Factor Analysis and survived scrutiny during critical evaluation of 
the component matrices of the pilot instrument clearly identify a complex array of people (IP 
managers (firm IP champions), consultants, researchers, patent attorneys, employees, 
financial report preparers, firm visitors, new market entrants, policy makers, external 
contractors), places (patent office, IP management committee, contractor firms) and things 
(third-party prior art, body of scientific knowledge, firm culture and strategic alliances) 
contributing to firms’ IP networks.  
 
The most common studies examine the nature of IP rights and are typified by the work of 
Levin et. al. (1987), who discovered from experts working in US manufacturing companies 
that they typically trust alternative strategies such as secrecy, managed lead time and 
 4
complementary sales and services more than formal intellectual property rights as a way of 
protecting their property. For an excellent recent review of issues related to IP management 
(Hansel, 2006). 
 
Scientific research papers have clearly identified specific problems that may exist within the 
biotechnology sector in terms of the granting and enforcement of intellectual property rights 
protecting biotechnology-related products and processes (Adler, 1984; Caulfield et al., 2006).  
The latter paper by Caulfield and co-authors sought to summarise some of the concerns raised 
within the community regarding the use of patents to protect rights associated with the 
discovery of particular genetic sequences, so-called ‘gene patents’, the resulting policy 
decisions and legislative changes resulting from these concerns, and whether the concerns 
raised have manifested in fact.   Specifically, Caulfield et al discuss whether the existence of a 
large number of patents for gene-related inventions, in combination with the myriad of 
owners of these patents, makes it difficult to acquire all necessary rights to carry out further 
research, thereby resulting in the underuse of valuable technologies – the so-called “tragedy 
of anticommons”.  Furthermore, Caulfield et al identified the risk that owners of patents 
protecting fundamental inventions in the sphere of genetics may assert their rights to exclude 
others, thereby preventing further development or access to the technologies.    
 
These concerns – as discussed by Caulfield - have been raised by a number of ‘controversies’ 
such as the Myriad Genetics’ decision to enforce patents related to the breast cancer genes 
BRCA1 and BRCA2, and has led to significant discussions between policy makers as to the 
impact of intellectual property rights on the inhibition, or otherwise, of research and 
development.   As an example, the Australian Advisory Council on Intellectual Property 
(ACIP) published a Report (2005, ACIP) on “Patents and Experimental Use” after a lengthy 
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consultation, and recommended that an exception to experimental use be included in the 
legislation to help alleviate concerns that patents provided a barrier to research.  However, to 
date, no legislative changes have been made in response to this recommendation. Despite 
these concerns, Caulfield et al found little evidence that these concerns had manifested as real 
problems – except possibly where patents protected inventions relating to diagnostic testing. 
They conclude a number of factors may be present which mitigate against the “tragedy of 
anticommons” and lack of access. Caulfield et al identified processes such as licencing, 
‘inventing around’ protected inventions, challenging the validity of patents, and exploiting the 
invention in jurisdictions where there is no patent protection as examples of such processes.  
All of these are avenues regularly used by researchers and organisations in other technology 
arenas.   In Australia, in December 2002, the Attorney General requested that the Australian 
Law Reform Commission investigate the practices governing IP rights over genetic materials 
and related products with a particular focus on human health issues. The reader is referred to 
the executive summary of the final report tabled in Australia’s parliament on 31 August 2004; 
it makes fascinating reading (Genes and Ingenuity: Gene Patenting and Human Health 
(ALRC 99)).  
 
The need for models of biotechnology intellectual property management has been clearly 
identified in the scientific literature as recently as 2002 (Gold et al., 2002). 
 
Intellectual property and its management by an organization falls within this previously 
defined ‘Organizational Capital’ category of intellectual capital, and organizational capital 
defines firm-value captured in systems, processes, and proprietary databases. It is these 
systems, processes and property databases which are critical for correct capturing of data 
necessary for IP registration and protection. What is unclear, however, is the critical path an 
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organization may take in achieving protection and property rights for its intangible assets. In 
high-technology firms like the biotechnology industry, allocation of scarce resources is very 
critical since most firms would juggle management and protection of a suite of IP rights with 
a view to commercialisation or early licensing. Royalties from early licensing versus full 
commercialisation of a discovery is often a choice imposed on the company by the growing 
pressure of dwindling cash reserves. More importantly full firm-value will not be realised, 
regardless of the actual legal protection offered by establishment of IP rights, without deeper 
knowledge of IP management practices and the measures which contribute to them. 
 
The remainder of this paper is structured as follows: 1) Instrument Development; 2) Results 
and Discussion; 3) Limitations; 4) Future Research; 5) References; and, 6) Appendices. 
 
Instrument Development and Survey Research Methods 
The design and construction of our measurement instrument was a combined effort from: 1) 
Lee, a management accounting academic with extensive survey research methods experience; 
2) White, a chartered accountant, business academic and former NH&MRC Senior Research 
Officer with extensive biotechnology experience; and, 3) Slater, a practicing IP management 
consultant with significant international experience. We designed the original instrument with 
the following considerations. It was hypothesized that firm IP managers needed to consider 
both sound accounting internal controls and management of the legal protection mechanisms. 
Seven important measures of IP management practice were proposed: 1) record-keeping and 
management practice; 2) capture and protection mechanisms; 3) the use of management 
services or traditional patent attorney services; 4) defensive measures; 5) business plan and 
strategic vision; 6) knowledge of the IP landscape; and, 7) promotion of IP culture in the firm.   
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Survey research methods consistent with Dilman (2000) and de Vaus (1991) were employed 
to mail the survey with an introductory letter and information sheet to 357 companies. The 
company names were obtained from two sources: 1) the AusBiotech (industry lobby group) 
Australian Biotechnology 2005, Directory of Australian Biotech; and, 2) the Australian Stock 
Exchange (ASX) biotechnology investor website1. Of the 357 potential respondents, 125 were 
listed biotechnology companies, which represented nearly the entire population of publicly-
listed biotechnology companies in Australia in July 2006. The response rate was only 19% 
with 68 completed surveys returned. The relatively low response rate can probably be 
attributed to the send-out time coinciding with the financial reporting period; some three 
months after financial year end in 2006.  
 
The IP manager’s responses to the seven measured dimensions of IP management practice 
were measured on a 5-point Likert-scale of extent of use, from (1) ‘not at all’  to (5) ‘to a 
great extent’. In developing individual items under each measure a comprehensive approach 
was taken, in other words we did not choose the most important IP management practices to 
question, but instead tried to ask about every IP management practice pertinent to that 
measure. This was done in anticipation of the Factor Analysis undertaken here identifying 
important measurement items. The number of individual items in each dimension of the 
measure was: 1) Record-keeping and management practices (22 items); 2) IP capture and 
protection mechanisms (10 items); 3) IP management services or traditional patent attorney 
services (9 items); 4) Defensive measures (12 items); 5) Business Plan and strategic vision (9 
items); 6) Knowledge of the IP landscape (9 items); and, 7) Promote an IP culture (7 items).  
 
                                                 
1 http://www.asx.com.au/investor/industry/biotech/index.htm 
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The individual Likert-scale scores for each of the 78 items were recorded in an SPSS 
database for each of the 68 respondent firms. Two of the responses had to be removed from 
the database because they were largely incomplete, resulting in the use of 66 questionnaires 
in the analyses. SPSS statistical analysis was done to measure: 1) factor loadings; and 2) 
Cronbach’s Alpha reliability measure of item loading Factor Analysis and Principle 
Component Analysis extraction method with Varimax and Kaiser Normalisation rotation 
method were used to identify the loading of factors measured by our instrument. The next 
section is combined results and discussion. 
 
Results and Discussion 
The responses from 66 surveys were entered into an SPSS database for statistical analysis. 
The coding master identified the item questions measured for each dimension of IP 
management practice as follows: 1) Record-keeping and management practice (RK1 to 
RK22); 2) IP Capture and protection mechanisms (C&P1 to C&P10); 3) IP Management 
services or traditional patent attorney services (MS/PA1 to MS/PA9); 4) Defensive measures 
(DM1 to DM12); 5) Business plan and strategic vision (BPSV1 to BPSV9); 6) Knowledge of 
the IP landscape (KNOW1 to KNOW9); and, 7) Promote IP culture (CULT1 to CULT7) 
(refer Appendix A – Measurement Instrument). 
 
Two tests were done of the datas’ suitability for further factor analysis (FA). First, the Kaiser-
Meyer-Olkin measure of sample adequacy (KMO) informs the proportion of variance which 
is common variance, which might be caused by underlying factors. A reported high value 
close to 1 indicates that factor analysis may be useful with the data. Generally a reported 
result of less than 0.5 would indicate that FA would not be useful. Second, a Bartlett’s test of 
sphericity (BTS) is a measure of whether the variables are unrelated, and very small 
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probability levels indicate a significant relationship probably does exist. Table 1 reports these 
test results for each of the seven measured dimensions of IP management practice.  
 
INSERT TABLE 1 HERE 
 
A factor analysis was conducted on each of the seven dimensions separately. In addition to 
the eigenvalue criterion (Kaiser, 1960), two other criteria were used to decide how many 
components to retain. They were the scree plot, which also retained the same number of 
components (Catell, 1966) and total explained variance of the components (Stevens, 1986). 
The eigenvalue, the percentage of explained variance, and the cumulative percentage for each 
component are reported in Table 2. 
 
INSERT TABLE 2 HERE 
 
The anti-image correlation matrix was examined next for values on the main diagonal less 
than 0.5 as this is a possible indicator that variables do not seem to fit with the structure of 
other variables. The items with an r<0.5 were excluded and a factor analysis was performed 
on the reduced items (presented in brackets for RK in Table 2 for the following analysis). The 
items excluded were RK2, RK3, RK4, RK5, RK6, RK7, RK8, RK13 and RK16 from the 
record keeping dimension after two rounds of factor analysis; each round excluding variables 
below 0.5 on the anti-image correlation matrix main diagonal. None of the variables in other 
dimensions were below the threshold level of 0.5. These results are presented in Table 3. 
 
INSERT TABLE 3 HERE 
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Record keeping and management practices    
The results of the factor analysis on the 22 item record keeping measure indicated that there 
were seven factors. However, this was reduced to only four factors that were loading reliably 
(discussed in the preceeding paragraph). See Table 4 for the component matrix for the four 
factors. Cronbach alphas were calculated for the four factors to test their reliability. They are 
0.782, 0.660, 0.547 and 0.552, respectively. The last two factors were removed from further 
analyses as the Cronbach’s alphas were below the lower limits of acceptability of 0.6 (Hair, et 
al, 1998). This resulted in two factors that can be reliably and validly measured using the 
instrument developed in this study. The first factor was named ‘physical records management’ 
because the items loading on it were concerned with the physical security of electronic 
documents, electronic devices and archived documents. The second factor was named 
‘records of firm IP’ as the three items loading on it are related to the maintenance of records 
such as the minutes of meeting where firm IP were discussed by management, regular 
database searches related to IP assets, and internal IP disclosure documents that employees 
use to record new knowledge.  
INSERT TABLE 4 HERE 
 
IP capture and protection mechanisms  
A factor analysis of this 10-item measure produced three factors. However, C&P9 and C&P5 
were removed from the analysis because their factor loadings were low. A second factor 
analysis of the remaining eight items produced two factors (see Table 5 for component 
matrix). The results showed that IP managers in the firms separated the external and internal 
aspects of IP capture and protection mechanisms. The first factor captured the external aspects 
of IP capture and protection mechanisms, as the items loading on this factor are concerned 
with the lodgement of patent applications, records of provisional or granted IP status, and 
renewal reminders from firm patent attorneys. The second factor, comprising of C&P1, 
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C&P2, and C&P7, measured the internal aspects of the capture and protection of IP, and items 
such as logged access to firm IP and maintenance of confidentiality agreements with 
employees. Reliability tests for the two factors produced high Cronbach alphas of 0.876 and 
0.753, respectively.  
INSERT TABLE 5 HERE 
 
  
IP management services or traditional patent attorney services   
The factor analysis of the MS/PA showed loading with Eigenvalues greater than one (Table 2) 
for three factors. The first factor comprises of five of the nine items. All the items relate to the 
seeking of advice or opinion in relation to firm IP, therefore this factor is named IP 
management advisory services. The second factor has three items (MS/PA7, MS/PA8 and 
MS/PA9) (see Table 6) and is named IP management control as the three items relate to the 
implementation of control systems within the firm, such as records management, audit and the 
production of policies and procedures. The isolation of question MS/PA2 from the other two 
factors seems logical in retrospect as that item measures, “Advice on your firm’s 
organisational structure”. The original intention was to have an item measuring advice about 
firm structure as it affects IP ownership rights, clearly the wording of the question was not 
carefully structured and this was detected by the respondents. In the revised instrument the 
question will be re-worded to, “Advice on IP ownership and the effect of organisational 
structure”. Cronbach’s alphas for the two factors are 0.824 and 0.869, respectively.  
 
INSERT TABLE 6 HERE 
 
Defensive measures    
Defensive measures were measured using a 12-item instrument. An exploratory factor 
analysis revealed two factors. However, three of the items were not clearly loading on either 
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of the factors (DM9, DM11, and DM12) and were removed from the analysis. Another factor 
analysis was run on the remaining nine items and also revealed two factors (see Table 7). All 
of the items making up the first factor relate to general defensive measures with respect to 
employees and contractors working with the firm. The second factor comprises of four items 
measures issues arising when staff join and leave the firm. Tests of reliability produced 
Cronbach alphas of 0.823 and 0.741 for the two factors, respectively.  
 
INSERT TABLE 7 HERE 
 
Business plan and strategic vision   
The nine-item instrument capturing business plan and strategic vision was factor analysed and 
produced two factors (see Table 8). The first factor, comprising of six items, is named 
strategic planning. The strategic planning dimension is concerned with the place of IP in the 
strategic planning of the firm. The second factor, IP risk management, comprises of three 
factors and the three items relate to the procedures and committees in place to manage the 
risks associated with the firm IP. The two factors were found to meet the reliability 
requirements, with Cronbach’s alphas of 0.860 and 0.743, respectively. 
 
INSERT TABLE 8 HERE 
 
Knowledge of the IP landscape   
Nine of the ten items measuring ‘knowledge of the IP landscape’ variables loaded on a single 
factor, except for KNOW7, “Use of regular searches and patent watches by a patent attorney 
or other professional”. Values for this KNOW7 variable from the principal component 
analysis were 0.587 for factor 1 and 0.633 for factor 2, which are not too dissimilar (see Table 
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9). For this reason all of the KNOW variables will be retained in the measure for the revised 
instrument. The test of reliability indicated that this instrument is acceptable with a 
Cronbach’s alpha of 0.880.  
 
INSERT TABLE 9 HERE 
 
Promote an IP culture   
A factor analysis of the seven items measuring the promotion of an IP culture showed two 
factors. CULT 5 was removed from the analysis and a subsequent exploratory factor analysis 
was performed (see Table 10). The first factor appears to includes the items relating to the 
promotion of IP research culture within the firm. Examples of items loading on factor one are 
state-of-the-art training, specialist IP management training and working with alliance partners. 
As a result, this factor will be named the promotion of IP research culture. The second factor, 
which comprises of CULT1 and CULT2, was probably perceived differently by respondents 
since those items refer to professional bodies such as AusBiotech (Australian biotechnology 
industry lobby group), and BIO (the equivalent world-wide body). The revised instrument 
will therefore delineate CULT1, and CULT2, as a factor related to interaction with the 
national and world-wide lobby groups through conference attendance and training. This factor 
will be named the promotion of IP professional culture. Reliability statistics for the two 
factors produced Cronbach alphas of 0.797 and 0.890, respectively. 
 
INSERT TABLE 10 HERE 
 
 14
The seven proposed dimensions of IP management practices in the original instrument has 
been re-stated into thirteen factors with high Cronbach’s Alphas (Cronbach, 1951). These new 
factors, along with their Cronbach’s alphas, are presented in Table 11. 
 
INSERT TABLE 11 HERE 
 
Limitations 
Firms in the biotechnology industry like other high-technology industries such as the 
semiconductor industry (Diabiaggio, 2007) are subject to collaborative outsourcing from the 
research and development to commercialisation stage of product development. One 
anticipated effect of the various strategic alliances formed by biotechnology firms is that 
measurement of IP management practices in a vertically disintegrated firm will be very 
different from a firm with high-level knowledge integration. Since our survey was piloted by 
random mail-out it does not take into consideration this effect on responses. 
 
Future Research 
The original 78-item measure of IP management practices could be trialled with another 
industry to discover whether factor loadings reveal unique differences in the perceptions of 
biotechnology firm IP managers and those in other industries. The revised instrument (Table 
11) can now be used in a larger study with appropriate independent variables to measure 
determinants of IP management practice. In addition, the anticipated measurement problem 
with vertically integrated and disintegrated firms, will inform a further study using a case 
study approach with vertically integrated and vertically disintegrated firm’s managers to 
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Table 1: The Kaiser-Meyer-Olkin measure of sampling adequacy and Bartlett’s test of 
sphericity for each dimension of the IP management practices measure. 
 
 
Variable KMO  BTS Chi-square BTS Sig. 
RK1 to RK22 0.560 462.094 0.000 
C&P1 to C&P10 0.696 280.413 0.000 
MSPA1 to MSPA9 0.807 259.909 0.000 
DM1 to DM12 0.814 268.836 0.000 
BPSV1 to BPSV9 0.856 245.567 0.000 
KNOW1 to KNOW9 0.835 272.974 0.000 




Table 2: Results of the factor analysis of the RK, C&P, MS/PA, DM, BPSV, KNOW and 
CULT dimensions of IP management practice, reporting number of loading factors 











RK 1 (1) 4.665 (3.922) 21.204 (30.172) 
 2 (2) 2.727 (1.661) 33.602 (42.947) 
 3 (3) 1.867 (1.446) 42.086 (54.070) 
 4 (4) 1.796 (1.214) 50.249 (63.407) 
 5 1.429 56.743 
 6 1.271 62.519 
 7 1.207 68.003 
C&P 1 3.699 36.993 
 2 2.059 57.582 
 3 1.225 69.832 
MS/PA 1 4.245 47.169 
 2 1.400 62.725 
 3 1.058 74.485 
DM 1 4.716 39.301 
 2 1.488 51.703 
BPSV 1 4.619 51.321 
 2 1.002 62.450 
KNOW 1 4.636 51.512 
 2 1.187 64.698 
CULT 1 3.148 44.970 
 2 1.368 64.512 
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RK 1 3.922 30.172 
 2  1.661 42.947 
 3  1.446 54.070 
 4  1.214 63.407 
 
Table 4: Component matrix for record keeping dimensions 
 
 
  Component 
  1 2 3 4 
RK18 .840 .297 .096 .108
RK17 .753 .331 .162 .052
RK14 .743 .110 .190 -.064
RK15 .667 -.200 -.076 .450
RK19 .149 .783 .237 .082
RK12 .116 .703 -.293 .277
RK10 .213 .649 .228 .083
RK21 .309 -.116 .759 .100
RK1 -.057 .341 .665 .191
RK20 .261 .327 .513 -.295
RK11 .076 .192 -.289 .768
RK22 .216 .067 .409 .615
RK9 -.006 .150 .218 .574
 
 




  Component 
  1 2 
C&P10 .879 .002 
C&P8 .872 -.052 
C&P4 .821 .092 
C&P3 .736 .400 
C&P6 .733 .070 
C&P1 -.080 .928 
C&P2 .005 .898 








  Component 
  1 2 3 
MS/PA5 .902 .066 -.082
MS/PA3 .783 .131 .342
MS/PA4 .735 .336 .182
MS/PA6 .673 .334 -.447
MS/PA1 .587 .287 .270
MS/PA8 .228 .878 -.096
MS/PA9 .125 .844 .204
MS/PA7 .271 .824 .249
MS/PA2 .168 .215 .833
 
 
Table 7: Component matrix for defensive measures 
 
 
  Component 












Table 8: Component matrix for business plan and strategic vision 
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Table 9: Component matrix for knowledge of IP landscape 
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Table 11: Reliability testing of each measure of firm IP management practices. 
Cronbach’s Alpha reliability measure (Alpha) are reported for each new (*) factor  
 
Item Description Alpha 
Physical records management 
RK18 Maintaining physical security over electronic storage devices and IT systems 
RK17 Maintaining physical security over document storage devices 
RK14 Archiving records after an appropriate period at a secure location 
RK15 Backup of IT storage devices 
0.782 
Records of firm IP 
RK19 Recording of regular database searches related to the firm’s IP assets 
RK12 Minutes of meetings where IP matters have been discussed by management 
RK10 IP disclosure documents for your employees to record the development of new 
knowledge 
0.660 
IP capture – external aspects 
C&P10 Lodgement of a PCT patent application 
C&P8 Lodgement of a provisional patent application 
C&P4 Hard-copy files of application for formal IP rights 
C&P3 Manual or electronic database records of provisional or granted IP status 
C&P6 Patent Attorney’s reminder system to track critical renewal dates 
0.876 
IP capture – internal aspects  
C&P1 Logged use of important copyright material et. Technical manuals, brochures and 
website materials 
C&P2 Logged use of the firm’s trade marks et. As used on documentation, advertising, 
packaging etc. 
C&P7 Confidentiality agreements and secure documentation for maintaining employee 
know-how and trade secrets 
0.753 
IP management advisory services 
MS/PA1 Business process improvements advice aimed at enhancing safeguards for the 
firm’s IP  
MS/PA3 Advice on IP ownership within the group  
MS/PA4 Advice on IP licensing management issues  
MS/PA5 Advice on applying for formal protection of IP 
MS/PA6 Opinions on validity or infringement of existing IP rights 
0.824 
IP management control 
MS/PA7 Setting up in-house IP records management system  
MS/PA8 Carrying out of an IP audit   
MS/PA9 Drafting of firm IP policies and procedures  
0.869 
General defensive measures 
DM2 Staff employment contracts contain IP provisions 
DM5 IP provisions are made in contracts with external contractors 
DM6 Contractors and visitors sign confidentiality agreements with the firm  
DM8 Management of disclosure and the publication process for knowledge relating to 
IP assets  
DM10 Controlling third-party IP disclosures by firm employees to outsiders. 
0.823 
Defensive measures relating to staff turnover 
DM1 Staff sign confidentiality agreements with the firm at commencement 
DM3 Exit interviews with departing employees address IP issues  
DM4 The Induction program with new employees reviews the firm’s IP policy 
documents and contractual obligations  




Table 11: Reliability testing of each measure of firm IP management practices. 




BPSV1 IP management issues discussed fully in the  business plan   
BPSV2 IP is an agenda item of all team meetings  
BPSV3 IP is addressed in the mission statement of the firm  
BPSV4 The business has an ‘IP Champion’ who manages all facets of the firm’s IP   
BPSV6 Strategic planning includes consideration of IP matters 
BPSV9 The firm budgets and plans for IP expenditure  
0.860 
IP risk management 
BPSV5 The business has an in-house patent attorney/IP lawyer  
BPSV7 Management has a documented IP policies and procedures manual  
BPSV8 An IP committee reviews IP matters and has responsibility for IP matters 
0.743 
Knowledge of the IP landscape 
KNOW1 Information about new entrants to your market  
KNOW2 Assessment of infringement risk against third parties  
KNOW3 Regular searches through free databases  
KNOW4 Regular searches through paid databases  
KNOW5 Regular review of scientific literature. 
KNOW6 Use of conferences and other literature 
KNOW8 Regular reviews of third-party prior art, either in-house or by patent attorney. 
KNOW9 Cross-referencing relevance of researched prior art to specific IP rights of the 
company 
0.880 
IP research culture 
CULT3 Firm employees attend state-of-the-art training for their field of expertise  
CULT4 Firm employees attend specialist IP management training  
CULT6 The firm’s IP Champion or IP consultant regularly conducts IP training sessions  
CULT7 Firm employees work directly with employees of strategic alliance partner on 
different projects 
0.797 
IP professional culture 
CULT1 Firm employees attend AusBiotech seminars 
CULT2 Firm employees attend BIO or AusBiotech conference annually 
0.890 
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APPENDIX A – MEASUREMENT INSTRUMENT 
 
1. To what extent is each of the following record-keeping  and management 
practices used in your firm? (Please circle one answer in each line): 
 
 







 To a 
great 
extent 
RK1 Authenticated (pages signed and dated) 
notebooks and diaries  
 
1 2 3 4 5 
RK2 Unauthenticated notebooks and diaries  
 1 2 3 4 5 
RK3 Saved emails communicating significant 
findings within the firm  
 
1 2 3 4 5 
RK4 Recorded telephone/verbal conversations 
discussing significant  
 
1 2 3 4 5 
RK5 Record-keeping in a proprietary (in-house 
developed) electronic database. 
 
1 2 3 4 5 
RK6 Record-keeping in an off-the-shelf 
electronic database  
 
1 2 3 4 5 
RK7 Saved soft-copies of protocols and 
procedures related to new knowledge  
 
1 2 3 4 5 
RK8 Printed hard-copies of protocols and 
procedures related to new knowledge  
 
1 2 3 4 5 
RK9 Personal notes maintained in the 
employees’ work area  
 
1 2 3 4 5 
RK10 Internal intellectual property (IP) 
disclosure documents for your employees 
to record the development of new 
knowledge  
 
1 2 3 4 5 
RK11 Filing of critical third-party agreements 
e.g. Disclosure agreements, confidentiality 
agreements, contracts, licenses and 
assignments. 
 
1 2 3 4 5 
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RK12 Minutes of meetings where IP matters have 
been discussed by management  
 
1 2 3 4 5 
RK13 Filing important correspondence on site 
 1 2 3 4 5 
RK14 Archiving records after an appropriate 
period at a secure location  
 
1 2 3 4 5 
RK15 Backup of IT storage devices  
 1 2 3 4 5 
RK16 Notification of the firm’s patent attorney of 
potential IP development  
 
1 2 3 4 5 
RK17 Maintaining physical security over 
document storage sites  
 
1 2 3 4 5 
RK18 Maintaining physical security over 
electronic storage devices and IT systems  
 
1 2 3 4 5 
RK19 Recording of regular database searches 
related to the firm’s IP assets  
 
1 2 3 4 5 
RK20 Does your company use software for email 
encryption? 
 
1 2 3 4 5 
RK21 Visitors sign in and wear identification 
badges, must read and sign documentation 
setting out their obligations 
 
1 2 3 4 5 
RK22 Keeping hard and soft-copies of relevant 
third-party prior art 
 
1 2 3 4 5 
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2. To what extent are each of the following Intellectual Property (IP) capture 

















Logged use of important copyright 
material e.g. technical manuals, 












C&P2 Logged use of the firm's trade marks e.g. 
as used on documentation, advertising, 
packaging etc. 
 
1 2 3 4 5 
C&P3 Manual or electronic database records of 
provisional or granted IP status  
 
1 2 3 4 5 
C&P4 Hard-copy files of application for formal 
IP rights 
 
1 2 3 4 5 
C&P5 In-house reminder system to track 
critical renewal dates  
 
1 2 3 4 5 
C&P6 Patent Attorney’s reminder system to 
track critical renewal dates  
 
1 2 3 4 5 
C&P7 Confidentiality agreements and secure 
documentation for maintaining employee 
know-how and trade secrets  
 
1 2 3 4 5 
C&P8 Lodgement of a provisional patent 
application 
 
1 2 3 4 5 
C&P9 Lodgement of an innovation patent 
 1 2 3 4 5 
C&P10 Lodgement of a PCT patent application 
 1 2 3 4 5 
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3. To what extent does your firm obtain the following IP management services 
or traditional patent attorney services? (Please circle one answer in each line) 
 
 







 To a 
great 
extent 
MS/PA1 Business process improvements advice 
aimed at enhancing safeguards for the 
firm’s IP  
 
1 2 3 4 5 
MS/PA2 Advice on your firm’s organizational 
structure  
 
1 2 3 4 5 
MS/PA3 Advice on IP ownership within the 
group  
 
1 2 3 4 5 
MS/PA4 Advice on IP licensing management 
issues  
 
1 2 3 4 5 
MS/PA5 Advice on applying for formal 
protection of IP 
 
1 2 3 4 5 
MS/PA6 Opinions on validity or infringement of 
existing IP rights 
 
1 2 3 4 5 
MS/PA7 Setting up in-house IP records 
management system  
 
1 2 3 4 5 
MS/PA8 Carrying out of an IP audit   
 1 2 3 4 5 
MS/PA9 Drafting of firm IP policies and 
procedures  
 
1 2 3 4 5 
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4. To what extent are the following defensive measures used in your firm 
to protect IP assets? (Please circle one answer in each line) 
 
 







 To a 
great 
extent 
DM1 Staff sign confidentiality agreements with 
the firm at commencement  
 
1 2 3 4 5 
DM2 Staff employment contracts contain IP 
provisions 
 
1 2 3 4 5 
DM3 Exit interviews with departing employees 
address IP issues  
 
1 2 3 4 5 
DM4 The Induction program with new 
employees reviews the firm’s IP policy 
documents and contractual obligations  
 
1 2 3 4 5 
DM5 IP provisions are made in contracts with 
external contractors 
 
1 2 3 4 5 
DM6 Contractors and visitors sign 
confidentiality agreements with the firm  
 
1 2 3 4 5 
DM7 Physical security measures are maintained 












DM8 Management of disclosure and the 
publication process for knowledge 
relating to IP assets  
 
1 2 3 4 5 
DM9 Management of continuous disclosure 
required by ASX listing-rules as it relates 












DM10 Controlling third-party IP disclosures by 
firm employees to outsiders. 
 
1 2 3 4 5 
DM11 Maintenance of hardware and software 
firewalls to protect valuable IT records  
 
1 2 3 4 5 
DM12 Use of appropriate document markings, 
such as “Confidential”,  ©, ™, ®. 
 
1 2 3 4 5 
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5. To what extent have the following IP management practices been part of 
your firm’s Business Plan and Strategic Vision from inception? (Please circle 
one answer in each line) 
 
 







 To a 
great 
extent 
BPSV1 IP management issues discussed fully in 
the  business plan   
 
1 2 3 4 5 
BPSV2 IP is an agenda item of all team 
meetings  
 
1 2 3 4 5 
BPSV3 IP is addressed in the mission statement 
of the firm  
 
1 2 3 4 5 
BPSV4 The business has an ‘IP Champion’ who 
manages all facets of the firm’s IP   
 
1 2 3 4 5 
BPSV5 The buiness has an in-house patent 
attorney/IP lawyer  
 
1 2 3 4 5 
BPSV6 Strategic planning includes 
consideration of IP matters 
 
1 2 3 4 5 
BPSV7 Management has a documented IP 
policies and procedures manual  
 
1 2 3 4 5 
BPSV8 An IP committee reviews IP matters and 
has responsibility for IP matters 
 
1 2 3 4 5 
BPSV9 The firm budgets and plans for IP 
expenditure  
 
1 2 3 4 5 
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6. To what extent have the following contributed to your firm’s knowledge of 
the IP landscape? (Please circle one answer in each line) 
 
 







 To a 
great 
extent 
KNOW1 Information about new entrants to 
your market  
 
1 2 3 4 5 
KNOW2 Assessment of infringement risk 
against third parties  
 
1 2 3 4 5 
KNOW3 Regular searches through free 
databases  
 
1 2 3 4 5 
KNOW4 Regular searches through paid 
databases  
 
1 2 3 4 5 
KNOW5 Regular review of scientific literature. 
 1 2 3 4 5 
KNOW6 Use of conferences and other literature 
 1 2 3 4 5 
KNOW7 Use of regular searches and patent 
watches by a patent attorney or other 
professional. 
 
1 2 3 4 5 
KNOW8 Regular reviews of third-party prior 
art, either in-house or by patent 
attorney. 
 
1 2 3 4 5 
KNOW9 Cross-referencing relevance of 
researched prior art to specific IP 
rights of the company 
 
1 2 3 4 5 
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7. To what extent does your firm promote an IP culture through the following 
education and training activities? (Please circle one answer in each line) 
 
 







 To a 
great 
extent 
CULT1 Firm employees attend AusBiotech 
seminars 
 
1 2 3 4 5 
CULT2 Firm employees attend BIO or 












CULT3 Firm employees attend state-of-the-art 












CULT4 Firm employees attend specialist IP 












CULT5 Firm employees attend professional 













CULT6 The firm’s IP Champion or IP 













CULT7 Firm employees work directly with 
employees of strategic alliance partner 
on different projects 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
  
 
 
 
 
 
